Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Boehringer Ingelheim
Mallinckrodt
Express Scripts
McKinsey

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Galunisertib

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Galunisertib: Sponsors, patents, clinical trial progress

Galunisertib is an investigational drug.

There have been 11 clinical trials for Galunisertib. The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2016.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Hepatocellular, and Adenocarcinoma. The leading clinical trial sponsors are Eli Lilly and Company, Azienda Ospedaliera Niguarda Cà Granda, and University of Turin, Italy.

There are five US patents protecting this investigational drug and fifty-one international patents.

Recent Clinical Trials for Galunisertib
TitleSponsorPhase
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal CancerAgendiaPhase 1/Phase 2
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal CancerAzienda Ospedaliera Niguarda Cà GrandaPhase 1/Phase 2
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal CancerCatalan Institute of HealthPhase 1/Phase 2

See all Galunisertib clinical trials

Clinical Trial Summary for Galunisertib

Top disease conditions for Galunisertib
Top clinical trial sponsors for Galunisertib

See all Galunisertib clinical trials

US Patents for Galunisertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Galunisertib   Start Trial Quinolinyl-pyrrolopyrazoles Eli Lilly and Company (Indianapolis, IN)   Start Trial
Galunisertib   Start Trial Quinolinyl-pyrrolopyrazoles Eli Lilly and Company (Indianapolis, IN)   Start Trial
Galunisertib   Start Trial TGF-.beta. inhibitors Eli Lilly and Company (Indianapolis, IN)   Start Trial
Galunisertib   Start Trial Compositions and methods for treating and preventing neointimal stenosis Yale University (New Haven, CT)   Start Trial
Galunisertib   Start Trial Methods for stimulating hematopoietic recovery by inhibiting TGF.beta. signaling Cornell University (Ithaca, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Galunisertib

Drugname Country Document Number Estimated Expiration Related US Patent
Galunisertib Austria 341550 2022-11-22   Start Trial
Galunisertib Australia 2003291643 2022-11-22   Start Trial
Galunisertib Brazil 0315337 2022-11-22   Start Trial
Galunisertib Canada 2501322 2022-11-22   Start Trial
Galunisertib China 100345852 2022-11-22   Start Trial
Galunisertib China 1714090 2022-11-22   Start Trial
Galunisertib Colombia 5570677 2022-11-22   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Medtronic
Express Scripts
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.